TP53 and neoplasm: Using cutting-edge treatments like MDM2 blockers or p53 reactivators, which work to restore the TP53 protein's normal function and slow tumor growth, clinicians can now specifically target the mutant TP53 pathway (Osman et al., 2020[136]).